The stock of ProMetic Life Sciences Inc. (TSE:PLI) is a huge mover today! About 364,975 shares traded hands. ProMetic Life Sciences Inc. (TSE:PLI) has declined 1.27% since March 11, 2016 and is downtrending. It has underperformed by 6.75% the S&P500.
The move comes after 9 months negative chart setup for the $1.88B company. It was reported on Oct, 18 by Barchart.com. We have $2.84 PT which if reached, will make TSE:PLI worth $150.40 million less.
ProMetic Life Sciences Inc. (TSE:PLI) Ratings Coverage
Out of 5 analysts covering ProMetic Life Sciences Inc. (TSE:PLI), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $6.70 is the highest target while $3 is the lowest. The $5.01 average target is 62.14% above today’s ($3.09) stock price. ProMetic Life Sciences Inc. has been the topic of 14 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Monday, August 10 by Scotia Capital. The stock of ProMetic Life Sciences Inc. (TSE:PLI) earned “Outperform” rating by RBC Capital Markets on Tuesday, December 8. The rating was maintained by RBC Capital Markets with “Outperform” on Monday, October 5. Paradigm Research reinitiated the stock with “Buy” rating in Monday, September 28 report. The firm has “Outperform” rating given on Tuesday, December 15 by RBC Capital Markets. The firm earned “Outperform” rating on Wednesday, June 15 by RBC Capital Markets. Scotia Capital maintained it with “Outperform” rating and $5 target price in Thursday, August 11 report. On Thursday, August 25 the stock rating was maintained by RBC Capital Markets with “Outperform”.
Another recent and important ProMetic Life Sciences Inc. (TSE:PLI) news was published by Marketwatch.com which published an article titled: “Thomvest Asset Management Inc. reports Prometic Life Sciences Inc. share …” on March 11, 2016.
ProMetic Life Sciences Inc. is a Canada biopharmaceutical company. The company has a market cap of $1.88 billion. The Firm has two divisions: Small Molecule Therapeutics and Protein Technology. It currently has negative earnings. The Firm offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.